Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Inmed Pharmaceuticals IN (IN.TO)

Inmed Pharmaceuticals IN (IN.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 33,732
  • Shares Outstanding, K 8,051
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,203 K
  • 60-Month Beta 2.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.62
Trade IN.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -1.33
  • Most Recent Earnings -0.37 on N/A
  • Next Earnings Date 05/13/21
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.30
  • Number of Estimates 1
  • High Estimate -0.30
  • Low Estimate -0.30
  • Prior Year -0.66
  • Growth Rate Est. (year over year) +54.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.35 +25.07%
on 04/20/21
4.85 -13.61%
on 04/08/21
-0.21 (-4.77%)
since 04/07/21
3-Month
3.35 +25.07%
on 04/20/21
7.06 -40.65%
on 02/09/21
-1.34 (-24.23%)
since 02/05/21
52-Week
3.35 +25.07%
on 04/20/21
13.86 -69.77%
on 06/03/20
-3.73 (-47.10%)
since 05/07/20

Most Recent Stories

More News
InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results

VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM; TSX:IN), a clinical-stage company developing pharmaceutical-based...

INM : 1.4800 (+0.68%)
IN.TO : 4.19 (-1.64%)
InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11th, 2021

VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based...

INM : 1.4800 (+0.68%)
IN.TO : 4.19 (-1.64%)
InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa

VANCOUVER, British Columbia, April 28, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a world leader in the clinical development of cannabinol...

INM : 1.4800 (+0.68%)
IN.TO : 4.19 (-1.64%)
InMed Pharmaceuticals Announces Voluntary Delisting from TSX

All common shares will continue to be listed and tradable on the Nasdaq

INM : 1.4800 (+0.68%)
IN.TO : 4.19 (-1.64%)
InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™

This yield level demonstrates commercial viability; supports advancing to large-scale production

INM : 1.4800 (+0.68%)
IN.TO : 4.19 (-1.64%)
InMed to Present at Virtual Conferences in March 2021

VANCOUVER, British Columbia, March 03, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based...

INM : 1.4800 (+0.68%)
IN.TO : 4.19 (-1.64%)
InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) (TSX: IN) Secures $8M in Underwritten Public Offering

InMed Pharmaceuticals (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol...

INM : 1.4800 (+0.68%)
IN.TO : 4.19 (-1.64%)
Edison issues update on InMed Pharmaceuticals (IN)

LONDON, UK / ACCESSWIRE / February 20, 2020 / InMed Pharmaceuticals (TSX:IN) recently announced that the first human clinical trial (755-101-HV) of its lead program, INM-755 for the treatment of epidermolysis...

IN.TO : 4.19 (-1.64%)
IMLFF : 4.8800 (-1.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 4.40
2nd Resistance Point 4.34
1st Resistance Point 4.26
Last Price 4.19
1st Support Level 4.12
2nd Support Level 4.06
3rd Support Level 3.98

See More

52-Week High 13.86
Fibonacci 61.8% 9.85
Fibonacci 50% 8.60
Fibonacci 38.2% 7.36
Last Price 4.19
52-Week Low 3.35

See More

Business Summary

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar